This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Apricus Biosciences Announces Poster Presentations On Progress Of PrevOnco(TM) In Combination With NexACT(R) Technology At The American Association For Cancer Research 2011 Annual Meeting

SAN DIEGO, March 22, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will present two posters at the American Association for Cancer Research ("AACR") 102 nd Annual Meeting to be held April 2-6, 2011 in Orlando, Florida.

The presentations will include one poster discussing how the Company's NexACT ® technology, involving a small molecule permeation enhancer called Dodecyl 2-(N,N dimethylamino) propionate ("DDAIP"), improves the pharmacokinetic profile of PrevOnco , Apricus Bio's proprietary drug for human hepatocellular carcinoma ("HCC") or liver cancer, in different species in mice, beagle dogs and cynomolgus monkeys. The second poster discusses the anti-tumor activity of PrevOnco in in vitro and in vivo human tumor models using a combination therapy of PrevOnco and Doxorubicin that resulted in a better efficacy profile with enhanced survival rate in a liver cancer model.

PrevOnco Posters

Title: DDAIP improves the pharmacokinetic profile of PrevOnco ® in different species: Comparison of DDAIP, CMC and PEG-300/400 formulations in mice, beagle dogs and cynomolgus monkeys. 

Abstract Number:  1297
April 4, 2011:  8:00 am to 12:00 pm ET
Session Title:  Pharmacokinetics and Metabolism
Session Category:  Clinical Research 5
Poster Section:  13
Board Number:  9

Title: PrevOnco exhibits anti-tumor activity in in vitro and in vivo human tumor models: Combination therapy (PrevOnco /Doxorubicin) demonstrates a better efficacy profile with enhanced survival rate in a liver cancer model.

Abstract Number:  2535
April 4, 2011: 1:00 pm to 5:00 pm ET
Session Title:  Chemotherapeutic Agents
Session Category:  Experimental and Molecular Therapeutics 15
Poster Section:  26
Board Number  20

About PrevOnco

PrevOnco is Apricus Bio's proprietary treatment for HCC or liver cancer. The product incorporates lansoprazole, a commonly marketed anti-ulcer compound which has shown strong anti-cancer activity in mice bearing human liver tumors. The U.S. Food & Drug Administration ("FDA") granted PrevOnco Orphan Drug status in August 2008. The Company is currently in discussions with the FDA regarding a Special Protocol Assessment ("SPA") Phase III protocol which was submitted in November 2011, and expects to have a final protocol agreed upon within eight to 12 months. 

About Apricus Biosciences, Inc.

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT ® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros ®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on sexual dysfunction, oncology, dermatology, autoimmune, pain, anti-infectives, diabetes and cosmeceuticals among others.

For further information on Apricus Bio, visit http://www.apricusbio.com and for information on its subsidiaries please visit www.nexmedusa.com or www.bio-quant.com . You can also find out more about the company by visiting http://twitter.com/apricusbio , http://facebook.com/apricusbio .

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, the FDA and other countries' regulatory approval of PrevOnco and other of its products and product candidates, its ability to commercialize such products and to enter into license agreements with potential pharmaceutical partners and obtain upfront and milestone payments as well as royalties and to achieve other of its financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

CONTACT: Apricus Biosciences, Inc.
         Edward Cox, V.P.
         Investor Relations & Corporate Development
         Apricus Bio, Inc.
         (858) 848-4249
         ecox@apricusbio.com
         
         Apricus Bio Investor Relations
         Paula Schwartz
         Rx Communications Group, LLC
         (917) 322-2216
         pschwartz@rxir.com

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs